Camostat: all 24 studies that test it

Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.

• Effect Camostat for Kidney Protection in Chronic Kidney DiseaseRecruitingNCT06794593Phase 2
• COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master ProtocolCompletedNCT04662086Phase 2Results posted
• COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-ProtocolTerminatedNCT04662073Phase 2Results posted
• The Potential of Camostat in COVID-19TerminatedNCT04625114Phase 2Results posted
• Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT)CompletedNCT04583592Phase 2Results posted
• Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 PatientsCompletedNCT04524663Phase 2Results posted
• ACTIV-2: A Study for Outpatients With COVID-19CompletedNCT04518410Phase 2/3Results posted
• Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19CompletedNCT04470544Phase 2Results posted
• A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1)TerminatedNCT04455815Phase 2Results posted
• Novel Agents for Treatment of High-risk COVID-19 Positive PatientsTerminatedNCT04374019Phase 2Results posted
• Camostat Mesylate in COVID-19 OutpatientsCompletedNCT04353284Phase 2Results posted
• Camostat Mesylate for Protein-losing Enteropathy After Fontan OperationCompletedNCT05474664Phase 2
• Safety and Pharmacokinetics Evaluation Study According to the Dose of Camostat Mesylate in Healthy VolunteersCompletedNCT04782505Phase 1
• Safety and Preliminary Efficacy of the Combination of Niclosamide and CamostatTerminatedNCT04750759Phase 2
• The DAWN Antivirals Trial for Ambulatory COVID-19 PatientsTerminatedNCT04730206Phase 3
• A Study of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2TerminatedNCT04721535Phase 3
• Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 PatientsTerminatedNCT04713176Phase 3
• Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk IndividualsCompletedNCT04681430Phase 2
• A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19)CompletedNCT04657497Phase 3
• CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult PatientsTerminatedNCT04608266Phase 3
• Multiple-dose Study of FOY-305 in Japanese Healthy Adult Male SubjectsCompletedNCT04451083Phase 1
• The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular ComplicationsWithdrawnNCT04435015Phase 1/2
• Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19WithdrawnNCT04338906Phase 4
• The Impact of Camostat Mesilate on COVID-19 InfectionCompletedNCT04321096Phase 1/2

← Camostat overview